ArticleEuropean heart journal. Case reports2026
Case report: VA-ECMO as a bridge to collapse in carcinoid heart disease.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carcinoid heart disease is a rare complication of neuroendocrine tumours caused by chronic exposure to vasoactive substances, leading to progressive valvular dysfunction and right heart failure. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in this context remains controversial, as it may exacerbate carcinoid crisis by bypassing the pulmonary metabolism of these vasoactive mediators. Case summary: We describe a patient with clinical suspicion of a neuroendocrine tumour and severe carcinoid heart disease who developed refractory cardiogenic shock. VA-ECMO was initiated as rescue support but resulted in an abrupt haemodynamic collapse, the patient subsequently progressed to multiorgan failure and died. This case illustrates the paradoxical and potentially deleterious effects of extracorporeal support in the setting of carcinoid physiology. Discussion: In the setting of a carcinoid crisis with cardiogenic shock secondary to right ventricular failure, VA-ECMO may appear as a potential option for haemodynamic support. However, by reducing pulmonary blood flow-and consequently the degradation of vasoactive substances-its use may worsen the patient's clinical condition. Therefore, a multidisciplinary approach involving cardiology, acute cardiac care, intensive care, oncology, gastroenterology, endocrinology, and pathology teams is essential, both in diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.